Clinical Trial Update: Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial of idarubicin and cytarabine with or without bevacizumab for newly diagnosed acute myeloid leukemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Basophilic Leukemia
• Eosinophilic Leukemia
• Erythroleukemia
• Megakaryoblastic Leukemia
• Monocytic Leukemia
• Myelomonocytic Leukemia

Drugs mentioned

• Bevacizumab (bevacizumab)
• CYTARABINE (CYTARABINE)
• Idarubicin (idarubicin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 2 | Status: TERMINATED